PARAGON (Completed)
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety. LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction
- Medicine
- LCZ696
- Population
- Heart failure
- Phase
- III
- Starting year
- 2013
- More information
- ClinicalTrials.gov